Sangui Biotech International Inc (SGBI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
352 SOUTH 200 WEST FARMINGTON, UT 84025 |
| State of Incorp. | CO |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 30 | 30 | 15 | 27 | 21 | 57 | |||
| Cash and cash equivalents | 30 | 30 | 15 | 27 | 21 | 57 | |||
| Receivables | 23 | 23 | 17 | 35 | 12 | ||||
| Prepaid expense | 12 | 12 | 13 | 9 | 21 | 3 | |||
| Other undisclosed current assets | 2 | 2 | 3 | 7 | 60 | 21 | |||
| Total current assets: | 68 | 67 | 49 | 79 | 102 | 94 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 1 | 2 | ||||||
| Other undisclosed noncurrent assets | 63 | 66 | 75 | ||||||
| Total noncurrent assets: | 63 | 67 | 77 | ||||||
| TOTAL ASSETS: | 131 | 134 | 125 | 79 | 102 | 94 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | |||||||||
| Accrued liabilities | |||||||||
| Debt | 708 | 753 | 619 | 478 | |||||
| Due to related parties | 72 | 62 | 42 | 28 | |||||
| Other undisclosed current liabilities | 156 | 140 | 131 | 164 | 453 | 354 | |||
| Total current liabilities: | 936 | 955 | 791 | 671 | 453 | 354 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 90 | 55 | 64 | ||||||
| Long-term debt, excluding current maturities | 49 | ||||||||
| Liabilities, other than long-term debt | |||||||||
| Operating lease, liability | 41 | 55 | 64 | ✕ | ✕ | ✕ | |||
| Other undisclosed noncurrent liabilities | (41) | (55) | (64) | ||||||
| Total noncurrent liabilities: | 90 | 55 | 64 | ||||||
| Total liabilities: | 1,026 | 1,009 | 855 | 671 | 453 | 354 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (239) | (224) | (83) | 49 | (351) | (261) | |||
| Common stock | 33,125 | 33,088 | 33,028 | 32,967 | 32,864 | 32,710 | |||
| Treasury stock, value | (19) | (19) | (19) | (19) | 19 | 19 | |||
| Additional paid in capital | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | |||
| Accumulated other comprehensive income | 97 | 90 | 92 | 91 | 93 | ||||
| Accumulated deficit | (37,955) | (37,895) | (37,696) | (37,504) | (37,180) | (36,978) | |||
| Other undisclosed equity, attributable to parent | (661) | (525) | |||||||
| Equity, attributable to noncontrolling interest | (656) | (652) | (647) | (641) | |||||
| Total equity: | (895) | (875) | (730) | (592) | (351) | (261) | |||
| TOTAL LIABILITIES AND EQUITY: | 131 | 134 | 125 | 79 | 102 | 94 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 69 | 66 | 29 | 88 | 77 | 68 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (0) | (1) | ||||||
| Gross profit: | 69 | 66 | 29 | 88 | 77 | 67 | ||
| Operating expenses | (209) | (217) | (210) | (426) | (285) | (384) | ||
| Operating loss: | (139) | (151) | (181) | (338) | (208) | (317) | ||
| Nonoperating income (expense) | 76 | (53) | (17) | (5) | 3 | |||
| Gain (loss), foreign currency transaction, before tax | 100 | (35) | 4 | 7 | 3 | |||
| Interest and debt expense | (23) | (18) | (14) | (12) | 8 | 9 | ||
| Loss from continuing operations before equity method investments, income taxes: | (86) | (222) | (213) | (354) | (200) | (304) | ||
| Other undisclosed loss from continuing operations before income taxes | (16) | (25) | ||||||
| Loss from continuing operations: | (86) | (222) | (213) | (354) | (216) | (330) | ||
| Income (loss) before gain (loss) on sale of properties: | (86) | (222) | (213) | (354) | (216) | (330) | ||
| Other undisclosed net income | 23 | 18 | 14 | 12 | ||||
| Net loss: | (63) | (204) | (199) | (343) | (216) | (330) | ||
| Other undisclosed net income (loss) attributable to parent | 4 | 5 | 6 | 19 | (29) | |||
| Net loss available to common stockholders, diluted: | (59) | (199) | (193) | (324) | (245) | (330) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (63) | (204) | (199) | (343) | (216) | (330) | ||
| Other comprehensive income | 56 | 206 | 198 | 344 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (7) | 2 | (0) | 1 | (216) | (330) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.